Member Info for busicat

The "no" vote will have put decisions on sales on hold - no procurement team wants to commit to orders from a supplier about to go insolvent

We are now at serious risk those in charge of procurement for the Scottish rollout will have to reconsider, given the supplier has just confirmed the obvious, which is the imminent risk of insolvency.

Mr Nugent has already said in his posts here

"It is not for me to finance the company or make suggestions on how I might / could / would be able to help"

No more cash imminent either

Onetimepost - Company law forces them to protect creditors first!

How do you know he's a successful investor?

All we know is he's been a successful property developer - very different

On the key issue of funding Mr Nugent has confirmed:

"I will state again, It is not down to me to fund this company in return for a board seat, I have never asked or agreed to this."

And his proposal is

"Seek / secure new funding but by allowing our shareholders first refusal since it is evident that from the retail offering there was huge demand that had to be scaled back massively for existing LTHs with only a small amount offered to them - even though it was increased slightly."

Why do so few see the high risk of the requirement to declare insolvency and cease trading becoming reality in the event of a "NO" vote, given no alternative financial plan has been offered?

Seeming £170k buy(?) suggests big money think this is the bottom?

13-Oct-25 10:16:18 1,700.00 10,000 Buy* 1,694.00 1,704.00 170.00k

Or was it a sell?!

Fall overdone??

From Hybridan today

"Hybridan Comment: Puzzlingly the share price is near a 52-week low despite the commercialisation progress which surely expands its funding options."

Oh dear, feeling the pain here and just twigged the likely impact of China's restrictions on rare earth minerals announced yesterday : (

As AI summarises, he'd be needing a big pile of cash ready then (50% of shares at ?2.93p?) :

"A mandatory takeover bid is triggered in UK public companies, including AIM-listed ones, when a person or group acquires 30% or more of the company's voting rights. This rule under the UK Takeover Code requires the individual or entity to make a mandatory offer for all remaining shares. Additionally, other events can trigger a bid requirement or suspension of trading on AIM, such as a reverse takeover or a significant transaction that results in a fundamental change in the company's business, board, or control, according to the AIM Rules.

Mandatory bid

Acquiring a stake of 30% or more of the voting shares necessitates a mandatory bid.

This is often referred to as a "Rule 9 offer" and must be made in cash, at no less than the highest price paid in the 12 months preceding the bid.

A mandatory bid is also triggered if parties acting "in concert" collectively hold more than 30% of the voting rights. "

I wonder if anyone saw the chairman's article last week.

https://genedrive.com/from-innovation-to-impact-genedrives-next-chapter/

I'll be gutted if the current shareholders' revolt ends up with no funds forthcoming and lights out before Christmas.

"We are now in active commercial rollout. We expect to double revenues from 2024 levels, reaching £1 million in 2025. Discussions with NHS Trusts and Integrated Care Boards across England are progressing, pilots and studies are going well across indications. We have been selected for national roll out in Scotland, and there is growing interest internationally, highlighting significant export potential as the company grows. For the first time, genedrive is building commercial momentum, positioning itself not only as a leader in the UK, but also a first mover on the global stage."

...and I see you mean £100k - even better!

...and I don't want to see the value of my existing shares inevitably plummet to well below 0.2 tomorrow on the back of a "No" vote!

Yet investors here seem determined to remove the possiblity of the one certain source of funding to keep Genedrive going beyond the next few weeks.

Extraordinary.

Yesterday Norfolk and Norwich University Hospitals NHS Foundation Trust published this:

"We're trialling a ground-breaking genetic test that could prevent critically ill newborn babies going deaf if treated with some commonly used antibiotics.

Our Neonatal Intensive Care Unit (NICU) is one of 14 sites across the UK to take part in the PALOH-UK (Pharmacogenetics to Avoid Loss of Hearing) study which screens for a genetic variant which is associated with an increased risk of deafness if they receive a certain type of antibiotic, called aminoglycosides.

Developed by researchers at Saint Mary’s Hospital, part of Manchester University NHS Foundation Trust (MFT) MFT Research and Innovation and The University of Manchester, in collaboration with Manchester-based firm Genedrive Diagnostics Ltd, the rapid bedside test could save the NHS £6 million every year by reducing the need for interventions, such as cochlear implants.

During the six-month trial period, every baby admitted to NICU will be offered a bedside test carried out by their nurse before they are given antibiotics.

Genedrive System_Left shadowUsing a cheek swab, the test can identify in just 26 minutes whether a critically ill baby admitted to intensive care has a gene variant that could result in permanent hearing loss if they are treated with a commonly used antibiotic, gentamicin.

While gentamicin is an effective antibiotic used to safely treat approximately 100,000 babies a year, one in 500 babies carry a gene variant that can result in permanent hearing loss when given the drug."

I don't know about buy quote, but the new Charts &Performance functionality is a disaster!

You're right Herrero. Plenty of data to pick you up.